Surveillance_NN for_IN Antiviral-Agent-Resistant_JJ Herpes_NP Simplex_NP Virus_NP in_IN the_DT General_NP Population_NP with_IN Recurrent_NP Herpes_NP Labialis_NP In_IN a_DT general_JJ population_NN survey_NN in_IN the_DT United_NP States_NPS ,_, the_DT prevalence_NN of_IN antiviral-agent-resistant_JJ herpes_NN simplex_NN virus_NN was_VBD very_RB low_JJ among_IN more_JJR than_IN 1,000_CD isolates_NNS from_IN individuals_NNS with_IN an_DT episode_NN of_IN recurrent_JJ herpes_NN labialis_NNS not_RB treated_VBN with_IN topical_JJ antiviral_JJ agents_NNS ._SENT Two_CD isolates_NNS had_VBD borderline_JJ resistance_NN to_TO acyclovir_NN (_( 0.2_CD %_NN )_) ,_, and_CC all_DT were_VBD susceptible_JJ to_TO penciclovir_NN ._SENT Between_IN October_NP 1998_CD and_CC February_NP 1999_CD ,_, a_DT study_NN was_VBD undertaken_VBN in_IN 10_CD states_NNS across_IN the_DT United_NP States_NPS to_TO determine_VB the_DT background_NN prevalence_NN of_IN herpes_NN simplex_JJ virus_NN (_( HSV_NP )_) resistant_NN to_TO acyclovir_NN or_CC penciclovir_NN among_IN isolates_NNS from_IN subjects_NNS with_IN an_DT episode_NN of_IN recurrent_JJ herpes_NN labialis_NNS (_( RHL_NP )_) which_WDT had_VBD not_RB been_VBN treated_VBN with_IN a_DT topical_JJ antiviral_JJ agent_NN ._SENT Results_NNS from_IN other_JJ studies_NNS with_IN immunocompetent_JJ patients_NNS with_IN HSV_NP infection_NN have_VBP shown_VBN that_IN the_DT prevalence_NN of_IN resistant_JJ virus_NN is_VBZ low_JJ (_( ,_, ,_, ;_: M._NP Reyes_NP ,_, J._NP Graber_NP ,_, N._NP Weatherall_NP ,_, C._NP Hodges-Savola_NP ,_, W._NP C._NP Reeves_NP ,_, and_CC the_DT Task_NP Force_NP on_IN Herpesvirus_NP Resistance_NP ,_, 11th_JJ International_NP Conference_NP on_IN Antiviral_NP Research_NP ,_, April_NP 1998_CD ,_, Antivir_NP ._SENT Res_NNS ._SENT 37:A44_NN [_SYM abstract_NN ]_SYM ,_, 1998_CD )_) and_CC stable_JJ ,_, despite_IN increasing_VBG rates_NNS of_IN use_NN of_IN antiviral_JJ medication_NN ._SENT Topical_JJ penciclovir_NN cream_NN was_VBD approved_VBN by_IN the_DT Food_NP and_CC Drug_NP Administration_NP in_IN 1996_CD as_IN a_DT prescription_NN product_NN for_IN the_DT treatment_NN of_IN RHL_NP ._SENT Topical_JJ acyclovir_NN cream_NN for_IN the_DT treatment_NN of_IN RHL_NP is_VBZ available_JJ in_IN many_JJ markets_NNS ,_, often_RB without_IN prescription_NN ,_, but_CC has_VBZ not_RB been_VBN approved_VBN for_IN use_NN in_IN the_DT United_NP States_NPS ._SENT The_DT survey_NN formed_VBD part_NN of_IN a_DT program_NN to_TO support_VB an_DT application_NN to_TO switch_VB penciclovir_NN from_IN a_DT prescription_NN product_NN to_TO a_DT nonprescription_NN product_NN (_( one_CD that_WDT could_MD be_VB sold_VBN over_IN the_DT counter_NN [_SYM OTC_NP ]_SYM )_) ._SENT It_PP was_VBD anticipated_VBN that_DT approval_NN for_IN OTC_NP use_NN will_MD increase_VB the_DT levels_NNS of_IN use_NN of_IN penciclovir_NN ,_, and_CC therefore_RB ,_, any_DT future_JJ change_NN in_IN the_DT prevalence_NN of_IN resistant_JJ virus_NN could_MD be_VB tracked_VBN against_IN a_DT background_NN prevalence_NN established_VBD prior_RB to_TO the_DT switch_NN to_TO OTC_NP status_NN ._SENT At_IN the_DT time_NN of_IN implementation_NN ,_, the_DT survey_NN was_VBD sponsored_VBN jointly_RB by_IN two_CD pharmaceutical_JJ companies_NNS and_CC was_VBD planned_VBN in_IN collaboration_NN with_IN the_DT Task_NP Force_NP on_IN Herpes_NP Simplex_NP Virus_NP Resistance_NP ._SENT (_( These_DT data_NNS were_VBD presented_VBN at_IN the_DT Thirteenth_NP International_NP Conference_NP on_IN Antiviral_NP Research_NP ,_, Baltimore_NP ,_, Md._NP ,_, April_NP 2000_CD ._SENT )_) The_DT study_NN was_VBD conducted_VBN in_IN accordance_NN with_IN good_JJ clinical_JJ practice_NN and_CC received_VBD Essex_NP Institutional_NP Review_NP Board_NP approval_NN ._SENT Pharmacists_NNS in_IN 47_CD community-based_JJ pharmacies_NNS were_VBD responsible_JJ for_IN the_DT clinical_JJ phase_NN of_IN the_DT study_NN ._SENT The_DT subjects_NNS volunteered_VBD for_IN the_DT study_NN in_IN response_NN to_TO advertisements_NNS placed_VBN in_IN the_DT media_NNS ._SENT Eligible_JJ subjects_NNS were_VBD aged_VBN >=12_JJ years_NNS and_CC had_VBD perioral_JJ herpes_NN labialis_NNS at_IN the_DT vesicle_NN or_CC soft_JJ ulcer_NN stage_NN ._SENT No_DT topical_JJ treatment_NN with_IN an_DT antiviral_JJ agent_NN was_VBD permitted_VBN prior_RB to_TO completion_NN of_IN the_DT study_NN ,_, although_IN subjects_NNS who_WP received_VBD any_DT oral_JJ antiviral_JJ agent_NN for_IN HSV_NP infection_NN were_VBD not_RB excluded_VBN ._SENT Efforts_NNS were_VBD made_VBN to_TO identify_VB individuals_NNS who_WP may_MD have_VB been_VBN immunocompromised_VBN by_IN asking_VBG subjects_NNS to_TO complete_VB one_CD page_NN of_IN the_DT case_NN report_NN form_NN ,_, which_WDT was_VBD then_RB sealed_VBN in_IN an_DT envelope_NN by_IN the_DT subject_NN to_TO maintain_VB confidentiality_NN and_CC subsequently_RB transferred_VBN to_TO the_DT data_NNS management_NN team_NN ._SENT Subjects_NNS responded_VBD to_TO questions_NNS on_IN medical_JJ history_NN (_( history_NN of_IN cancer_NN ,_, human_JJ immunodeficiency_NN virus_NN infection_NN [_SYM HIV_NP ]_SYM or_CC AIDS_NP ,_, or_CC organ_NN transplantation_NN )_) and_CC completed_VBD a_DT checklist_NN of_IN medications_NNS that_IN they_PP were_VBD taking_VBG ,_, use_NN of_IN which_WDT may_MD have_VB implied_VBN that_IN the_DT subject_NN was_VBD immunocompromised_VBN ._SENT The_DT checklist_NN specified_VBN drugs_NNS with_IN immunosuppressant_JJ activity_NN or_CC drugs_NNS used_VBN to_TO treat_VB HIV_NP infection_NN or_CC AIDS_NP or_CC other_JJ diseases_NNS associated_VBN with_IN defects_NNS of_IN the_DT immune_JJ system_NN ._SENT A_DT total_NN of_IN 1,803_CD subjects_NNS were_VBD recruited_VBN ,_, and_CC each_DT subject_NN was_VBD swabbed_VBN once_RB ._SENT The_DT study_NN population_NN (_( n_NN =_SYM 1,795_CD subjects_NNS with_IN swabs_NNS processed_VBN for_IN virus_NN isolation_NN )_) was_VBD principally_RB female_JJ (_( 67.6_CD %_NN )_) ,_, with_IN a_DT mean_JJ age_NN of_IN 37.5_CD years_NNS (_( standard_JJ deviation_NN [_SYM SD_NP ]_SYM ,_, 15.34_CD years_NNS )_) ._SENT Caucasians_NNS formed_VBD the_DT largest_JJS racial_JJ group_NN (_( 89.9_CD %_NN )_) ._SENT The_DT preponderance_NN of_IN female_JJ Caucasians_NNS in_IN the_DT study_NN may_MD reflect_VB that_DT sector_NN of_IN the_DT population_NN that_WDT is_VBZ concerned_VBN about_IN RHL_NP and/or_CC that_WDT is_VBZ motivated_VBN to_TO seek_VB treatment_NN ._SENT The_DT mean_JJ +-_NN SD_NN number_NN of_IN episodes_NNS experienced_VBN during_IN the_DT previous_JJ 12_CD months_NNS was_VBD 5.2_CD +-_NN 5.26_CD ,_, and_CC the_DT mean_JJ age_NN at_IN the_DT first_JJ episode_NN was_VBD 13.1_CD years_NNS ._SENT The_DT mean_JJ +-_NN SD_NN duration_NN of_IN an_DT episode_NN of_IN RHL_NP was_VBD reported_VBN to_TO be_VB 8.1_CD +-_NN 4.8_CD days_NNS ._SENT Lesions_NNS were_VBD swabbed_VBN by_IN the_DT pharmacist_NN ._SENT The_DT swabs_NNS were_VBD stored_VBN in_IN transport_NN medium_NN at_IN 4C_JJ and_CC shipped_VBN to_TO a_DT central_JJ laboratory_NN within_IN 3_CD to_TO 4_CD days_NNS ._SENT Virus_NN was_VBD isolated_VBN in_IN primary_JJ rabbit_NN kidney_NN cells_NNS ._SENT A_DT cell_NN suspension_NN prepared_VBN from_IN each_DT infected_JJ culture_NN was_VBD used_VBN to_TO type_VB the_DT virus_NN by_IN indirect_JJ immunofluorescence_NN ._SENT Vero_NP cells_NNS and_CC MRC-5_JJ cells_NNS were_VBD used_VBN for_IN the_DT plaque_NN reduction_NN assays_NNS with_IN acyclovir_NN and_CC penciclovir_NN ,_, respectively_RB ._SENT Monolayers_NNS in_IN six-well_NN plates_NNS were_VBD infected_VBN with_IN 50_CD to_TO 100_CD PFU_NN per_IN well_RB ._SENT After_IN adsorption_NN ,_, the_DT inoculum_NN was_VBD removed_VBN and_CC replaced_VBN with_IN culture_NN medium_NN containing_VBG methylcellulose_NN (_( 2_CD %_NN )_) and_CC the_DT test_NN antiviral_JJ agent_NN (_( final_JJ concentrations_NNS ,_, 0_CD to_TO 30_CD mug/ml_NN ,_, tested_VBN in_IN duplicate_NN )_) ._SENT After_IN incubation_NN for_IN 3_CD days_NNS at_IN 36_CD +-_NN 1C_NN in_IN 5_CD to_TO 7_CD %_NN CO2_NP ,_, the_DT monolayers_NNS were_VBD fixed_VBN and_CC stained_VBN ,_, the_DT plaques_NNS were_VBD counted_VBN ,_, and_CC the_DT 50_CD %_NN inhibitory_JJ concentrations_NNS (_( IC50s_NP )_) were_VBD calculated_VBN ._SENT Two_CD standard_JJ HSV_NP type_NN 1_CD (_( HSV-1_NP )_) reference_NN strains_NNS were_VBD included_VBN in_IN all_DT assays_NNS ,_, SC16_NP (_( which_WDT is_VBZ sensitive_JJ to_TO acyclovir_NN and_CC penciclovir_NN )_) and_CC DM21_NP (_( a_DT thymidine_NN kinase-negative_JJ mutant_NN which_WDT is_VBZ resistant_JJ to_TO acyclovir_NN and_CC penciclovir_NN )_) ._SENT Summary_JJ IC50_NP data_NNS for_IN these_DT strains_NNS are_VBP provided_VBN in_IN Table_NP ._SENT TABLE_NN 1_CD |_SYM Summary_NN of_IN HSV-1_JJ susceptibility_NN to_TO acyclovir_NN and_CC penciclovir_NN by_IN antiviral_JJ use_NN and_CC medical_JJ history_NN The_DT 1,803_CD cultures_NNS yielded_VBD 1,087_CD isolates_NNS ,_, all_DT of_IN which_WDT were_VBD typed_VBN as_IN HSV-1_NP ._SENT A_DT total_NN of_IN 1,002_CD isolates_NNS were_VBD tested_VBN for_IN their_PP$ susceptibilities_NNS to_TO acyclovir_NN and_CC penciclovir_NN ,_, and_CC 2_CD additional_JJ isolates_NNS were_VBD also_RB tested_VBN for_IN their_PP$ susceptibilities_NNS to_TO penciclovir_NN ._SENT The_DT breakpoint_NN for_IN defining_VBG resistance_NN to_TO acyclovir_NN was_VBD an_DT IC50_NP >=2_NN mug/ml_NN ._SENT Two_CD criteria_NNS were_VBD applied_VBN to_TO define_VB penciclovir_NN resistance_NN :_: (_( i_NP )_) an_DT IC50_NP >=2_NN mug/ml_NN and_CC (_( ii_NNS )_) an_DT IC50_NP three_CD or_CC more_JJR times_CC greater_JJR than_IN the_DT mean_JJ IC50_NN of_IN penciclovir_NN for_IN all_DT isolates_NNS in_IN the_DT survey_NN (_( >=0.84_JJ mug/ml_NN )_) ._SENT Two_CD HSV-1_NP isolates_NNS were_VBD confirmed_VBN to_TO be_VB resistant_JJ to_TO acyclovir_NN (_( IC50s_NP ,_, 3.21_CD and_CC 2.41_CD mug/ml_NN ,_, respectively_RB )_) ,_, but_CC resistance_NN was_VBD borderline_JJ in_IN this_DT assay_NN and_CC in_IN the_DT original_JJ assay_NN (_( IC50s_NP ,_, 2.21_CD and_CC 4.35_CD mug/ml_NN ,_, respectively_RB )_) ._SENT Both_DT isolates_NNS were_VBD sensitive_JJ to_TO penciclovir_NP (_( IC50s_NP ,_, 0.38_CD and_CC 0.34_CD mug/ml_NN ,_, respectively_RB )_) ._SENT The_DT two_CD subjects_NNS with_IN acyclovir-resistant_JJ HSV-1_NP isolates_NNS were_VBD immunocompetent_JJ ;_: one_CD subject_NN had_VBD no_DT history_NN of_IN antiviral_JJ agent_NN use_NN ,_, and_CC the_DT other_JJ subject_NN reported_VBD prior_RB use_VB of_IN acyclovir_NN (_( not_RB during_IN the_DT episode_NN evaluated_VBN for_IN the_DT present_JJ study_NN )_) ._SENT All_DT other_JJ isolates_NNS were_VBD susceptible_JJ to_TO acyclovir_NN ;_: therefore_RB ,_, the_DT prevalence_NN of_IN acyclovir-resistant_JJ HSV-1_NP isolates_NNS was_VBD 0.20_CD %_NN (_( 2_CD of_IN 1,002_CD isolates_NNS tested_VBN ;_: 95_CD %_NN confidence_NN interval_NN ,_, 0.02_CD to_TO 0.72_CD %_NN )_) ._SENT A_DT total_NN of_IN 1,004_CD HSV-1_JJ isolates_NNS were_VBD tested_VBN for_IN their_PP$ susceptibilities_NNS to_TO penciclovir_NN ,_, and_CC none_NN was_VBD found_VBN to_TO be_VB resistant_JJ (_( 0_CD of_IN 1,004_CD isolates_NNS tested_VBN ;_: prevalence_NN ,_, 0.00_CD %_NN ;_: 95_CD %_NN confidence_NN interval_NN ,_, 0.00_CD to_TO 0.37_CD %_NN )_) ._SENT These_DT results_NNS are_VBP consistent_JJ with_IN data_NNS from_IN a_DT similar_JJ survey_NN conducted_VBN in_IN the_DT United_NP Kingdom_NP at_IN a_DT time_NN when_WRB topical_JJ acyclovir_NN had_VBD been_VBN available_JJ OTC_NN for_IN 5_CD years_NNS and_CC topical_JJ penciclovir_NN had_VBD been_VBN available_JJ as_IN a_DT prescription_NN medicine_NN for_IN 2_CD years_NNS ._SENT One_CD resistant_JJ HSV-1_JJ isolate_NN which_WDT was_VBD cross_NN resistant_JJ to_TO acyclovir_NN and_CC penciclovir_NN was_VBD identified_VBN (_( 1_CD of_IN 924_CD isolates_NNS tested_VBN for_IN susceptibility_NN to_TO acyclovir_NN ;_: 1_CD of_IN 915_CD isolates_NNS tested_VBN for_IN susceptibility_NN to_TO penciclovir_NN ;_: prevalence_NN ,_, 0.1_CD %_NN )_) ._SENT Other_JJ surveys_NNS with_IN immunocompetent_JJ populations_NNS ,_, predominantly_RB ,_, patients_NNS with_IN genital_JJ herpes_NN ,_, have_VBP reported_VBN a_DT prevalence_NN of_IN HSV_NP resistance_NN of_IN 0.1_CD to_TO 0.7_CD %_NN (_( ,_, ;_: Reyes_NP et_FW al._FW ,_, Antivir_NN ._SENT Res_NNS ._SENT 37:A44_NN [_SYM abstract_NN ]_SYM ,_, 1998_CD )_) ._SENT The_DT historical_JJ prevalence_NN of_IN acyclovir-resistant_JJ HSV_NP isolates_NNS among_IN untreated_JJ ,_, immunocompetent_JJ patients_NNS ,_, as_RB measured_VBN by_IN the_DT plaque_NN reduction_NN assay_NN ,_, is_VBZ 0.3_CD %_NN ._SENT Resistant_JJ HSV_NP is_VBZ more_RBR common_JJ in_IN immunocompromised_JJ patients_NNS ;_: for_IN example_NN ,_, in_IN a_DT surveillance_NN study_NN by_IN Reyes_NP et_FW al._FW (_( Reyes_NP et_FW al._FW ,_, Antivir_NN ._SENT Res_NNS ._SENT 37:A44_NN [_SYM abstract_NN ]_SYM ,_, 1998_CD )_) ,_, 4_CD of_IN 62_CD (_( 6.5_CD %_NN )_) isolates_VBZ from_IN HIV-infected_JJ patients_NNS were_VBD resistant_JJ to_TO acyclovir_NN ._SENT IC50_JJ data_NNS from_IN the_DT present_JJ survey_NN were_VBD analyzed_VBN to_TO investigate_VB differences_NNS in_IN the_DT susceptibilities_NNS of_IN isolates_NNS from_IN the_DT study_NN subjects_NNS to_TO acyclovir_NN and_CC penciclovir_NN on_IN the_DT basis_NN of_IN their_PP$ reported_VBN use_NN of_IN antiviral_JJ agents_NNS ,_, immunocompetence_NN ,_, or_CC history_NN of_IN RHL_NP ._SENT For_IN isolates_NNS from_IN subjects_NNS who_WP reported_VBD use_NN of_IN antiviral_JJ medication_NN to_TO treat_VB herpesvirus_NN infections_NNS ,_, the_DT median_JJ IC50_NN was_VBD similar_JJ to_TO the_DT median_JJ IC50_NN for_IN isolates_NNS from_IN subjects_NNS who_WP had_VBD never_RB used_VBN antiviral_JJ medication_NN both_CC for_IN acyclovir_NN (_( P_NN =_SYM 0.211_CD )_) and_CC for_IN penciclovir_NN (_( P_NN =_SYM 0.649_CD )_) ._SENT For_IN the_DT small_JJ number_NN of_IN isolates_NNS (_( n_NN =_SYM 49_CD )_) from_IN subjects_NNS who_WP used_VBD oral_JJ acyclovir_NN ,_, famciclovir_NN ,_, or_CC valacyclovir_NN at_IN the_DT time_NN of_IN the_DT study_NN ,_, the_DT median_JJ IC50_NN of_IN acyclovir_NN (_( 0.31_CD mug/ml_NN )_) was_VBD significantly_RB lower_JJR than_IN that_IN for_IN isolates_NNS from_IN subjects_NNS who_WP were_VBD not_RB using_VBG antiviral_JJ medication_NN (_( 0.43_CD mug/ml_NN )_) (_( P_NN =_SYM 0.025_CD )_) ._SENT This_DT difference_NN is_VBZ not_RB clinically_RB important_JJ and_CC may_MD simply_RB have_VB arisen_VBN by_IN chance_NN ;_: the_DT parallel_JJ comparison_NN for_IN penciclovir_NN showed_VBD no_DT significant_JJ difference_NN (_( P_NN =_SYM 0.488_CD )_) ._SENT No_DT other_JJ comparisons_NNS reached_VBD statistical_JJ significance_NN ,_, including_VBG that_IN for_IN immune_JJ status_NN ,_, although_IN the_DT number_NN of_IN subjects_NNS in_IN this_DT survey_NN who_WP may_MD have_VB been_VBN immunocompromised_VBN was_VBD low_JJ ._SENT In_IN conclusion_NN ,_, the_DT prevalence_NN of_IN resistant_JJ HSV-1_JJ strains_NNS among_IN isolates_NNS from_IN the_DT general_JJ population_NN with_IN RHL_NP is_VBZ low_JJ ,_, consistent_JJ with_IN earlier_JJR surveys_NNS with_IN immunocompetent_JJ patients_NNS with_IN HSV_NP infection_NN ,_, despite_IN the_DT increasing_VBG rate_NN of_IN use_NN of_IN herpesvirus-specific_JJ antiviral_JJ agents_NNS over_IN the_DT past_JJ two_CD decades_NNS ._SENT 